AR115254A1 - PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCER - Google Patents
PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERInfo
- Publication number
- AR115254A1 AR115254A1 ARP190100428A ARP190100428A AR115254A1 AR 115254 A1 AR115254 A1 AR 115254A1 AR P190100428 A ARP190100428 A AR P190100428A AR P190100428 A ARP190100428 A AR P190100428A AR 115254 A1 AR115254 A1 AR 115254A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- combination
- cancer
- immunotherapy against
- different types
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente se refiere a la inmunoterapia contra el cáncer. La presente se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacúnales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.This refers to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, this is concerned with immunotherapy against cancer. The present also refers to peptide epitopes for tumor-associated T lymphocytes, alone or in combination with other tumor-associated peptides that, for example, can serve as active pharmaceutical ingredients in vaccine compositions intended to stimulate antitumor immune responses, or to stimulate ex vivo. T lymphocytes that will later be transferred to patients. Peptides bound to major histocompatibility complex (MHC) molecules, or peptides as such, can also be targets of antibodies, soluble T cell receptors, and other binding molecules.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102018103944 | 2018-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115254A1 true AR115254A1 (en) | 2020-12-16 |
Family
ID=74446241
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100428A AR115254A1 (en) | 2018-02-21 | 2019-02-20 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCER |
| ARP200102429A AR119861A2 (en) | 2018-02-21 | 2020-08-28 | PEPTIDE, NUCLEIC ACID THAT ENCODS IT, ANTIBODY OR FRAGMENT THEREOF THAT RECOGNIZES IT, T-LYMPHOCYTE RECEPTOR THAT REACTS WITH IT, HOST CELL THAT COMPRISES THEM, RELATED METHOD, PHARMACEUTICAL COMPOSITION AND KIT |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102429A AR119861A2 (en) | 2018-02-21 | 2020-08-28 | PEPTIDE, NUCLEIC ACID THAT ENCODS IT, ANTIBODY OR FRAGMENT THEREOF THAT RECOGNIZES IT, T-LYMPHOCYTE RECEPTOR THAT REACTS WITH IT, HOST CELL THAT COMPRISES THEM, RELATED METHOD, PHARMACEUTICAL COMPOSITION AND KIT |
Country Status (1)
| Country | Link |
|---|---|
| AR (2) | AR115254A1 (en) |
-
2019
- 2019-02-20 AR ARP190100428A patent/AR115254A1/en unknown
-
2020
- 2020-08-28 AR ARP200102429A patent/AR119861A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR119861A2 (en) | 2022-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002123A1 (en) | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancer. | |
| CL2023001346A1 (en) | Use of peptides in immunotherapy against small cell lung cancer and others. | |
| CO2018008763A2 (en) | Peptides, combinations of peptides and cells for use in immunotherapy against urinary bladder cancer and other types of cancer | |
| CL2018000780A1 (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other types of cancer | |
| CO2018010284A2 (en) | Treatments against uterine cancer | |
| CL2021002459A1 (en) | Peptides and peptide combinations for use in cancer immunotherapy (divisional of application no. 201902093) | |
| CO2019012077A2 (en) | Peptides and combinations thereof for use in immunotherapy against various types of cancer | |
| CO2021004270A2 (en) | B * 44 Restricted Peptides for Use in Cancer Immunotherapy and Related Methods | |
| CO2021000534A2 (en) | Immunotherapy with b * 07-restricted peptides and a combination of anticancer peptides and related methods | |
| CO2019012071A2 (en) | Peptides and peptide combinations for use in immunotherapy against leukemia and other cancers | |
| CO2021003404A2 (en) | Immunotherapy with a * 01-restricted peptides and a combination of anticancer peptides and related methods | |
| CL2021000177A1 (en) | Peptides, peptide combinations, cells and kits for use in cancer immunotherapy (divisional application no. 201802360) | |
| AR112331A1 (en) | PEPTIDES AND PEPTID COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | |
| CO2018012294A2 (en) | Immunotherapy against melanoma and other types of cancer | |
| CL2022003381A1 (en) | a*03-restricted peptides, use in cancer immunotherapy and related methods (split application 202003371) | |
| CO2020013652A2 (en) | Peptides for use in cancer immunotherapy | |
| CL2021001012A1 (en) | Peptides and peptide combinations for use in immunotherapy against small cell lung cancer and other types of cancer (divisional application no. 201800780) | |
| CL2020002857A1 (en) | New peptides (seq id no: 146) and new peptide combinations for use in immunotherapy against non-Hodgkin's lymphoma (NHL) and other cancers (divisional application no. 201802096) | |
| AR115254A1 (en) | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCER | |
| AR114532A1 (en) | PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER | |
| AR114736A1 (en) | PEPTIDES RESTRICTED BY B * 44 FOR USE IN IMMUNOTHERAPY AGAINST CANCER AND RELATED METHODS | |
| AR117437A1 (en) | IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 08 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS | |
| AR115881A1 (en) | IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 07 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS | |
| AR113027A2 (en) | PEPTIDES, PEPTIDE COMBINATIONS AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCER |